Stay informed with the latest market-moving news and analysis
SHANGHAI, Jan. 21, 2026 /PRNewswire/ -- At today's opening of BETT 2026, Al-Powered STEM Education Solution Provider DFRobot is presenting a range of interactive AI and robotics learning solutions at Stand SM23 in London's ExCeL Centre. The exhibit demonstrates Artificial Intelligence...
ALACHUA, Fla. and TAMPA, Fla., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced the pricing of an upsized underwritten public offering of 4,000,000 shares of its common stock at a price to the public of $31.00 per share, before underwriting discounts and commissions. All of the shares to be sold in the proposed offering are to be sold by Axogen. In addition, Axogen has granted the underwriters a 30-day option to purchase up to an additional 600,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds to Axogen from the proposed offering, before deducting underwriters’ discounts and commissions and other offering expenses payable by Axogen, are expected to be approximately $124 million (assuming no exercise of the underwriters’ option to purchase additional shares).
Panelists include leaders in the fields of science, medicine and technology: Jack Hidary, Dr. Edward Neilan, Dr. Shoshana Shendelman, Dr. John Greely, Louis Reese and Nadia Harhen. NEW YORK, Jan. 21, 2026 /PRNewswire/ -- Introducing the inaugural Cures Conference to be held in NYC on...
SOUTH SAN FRANCISCO, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the pricing of an upsized underwritten public offering of 7,900,677 shares of its common stock at a price to the public of $22.15 per share. Gross proceeds from the underwritten public offering before deducting underwriting discounts and commissions and estimated offering expenses are expected to be approximately $175.0 million. All of the shares of common stock are being offered by Corvus. In addition, Corvus has granted the underwriters of the offering a 30-day option to purchase up to an additional 1,185,101 shares of common stock at the public offering price, less underwriting discounts and commissions.
EMERYVILLE, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge", “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced the pricing of its upsized underwritten public offering of 5,897,435 shares of its common stock at a price to the public of $19.50 per share. The gross proceeds from this offering are expected to be approximately $115.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by BioAge. The offering is expected to close on or about January 23, 2026, subject to the satisfaction of customary closing conditions. In addition, BioAge has granted the underwriters a 30-day option to purchase up to an additional 884,615 shares of common stock in connection with the offering. All of the shares of common stock are being offered by BioAge.
Approximately 3,300 CenterPoint employees and contract workers supporting storm preparation and potential restoration efforts across Houston and parts of Southeast Texas State of Texas emergency response resources activated ahead of potential impacts ERCOT Weather Watch issued for...
DUBAI, United Arab Emirates, Jan. 22, 2026 /PRNewswire/ -- Montran, the global leader in financial infrastructure and payment solutions, today announced the opening of its new Middle East & North Africa (MENA) regional office, which is based out of Dubai, United Arab Emirates. The...
BEIJING, Jan. 21, 2026 /PRNewswire/ -- With a click on their cellphone screens, fruit farmers in Xi County, north China's Shanxi Province can finish irrigating and fertilizing their Yulu fragrant pear orchards, which is nothing but a common sight there. Famed for its time-honored pear...
NEW YORK--(BUSINESS WIRE)--BitGo Holdings, Inc. (“BitGo”), the digital asset infrastructure company, announced today the pricing of its initial public offering of an aggregate of 11,821,595 shares of Class A common stock at a price to the public of $18.00 per share. The offering consists of 11,026,365 shares of Class A common stock being offered by BitGo and 795,230 shares of Class A common stock being offered by certain existing stockholders of BitGo. BitGo will not receive any proceeds from t
NEW YORK, Jan. 21, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of StubHub Holdings, Inc. (NYSE: STUB) pursuant and/or traceable to the Registration Statement issued in connection with StubHub's September 2025 initial...
DAVOS, Switzerland, Jan. 21, 2026 /PRNewswire/ -- At the Annual Meeting of World Economic Forum (WEF) in Davos, Dowson Tong, Senior Executive Vice-President of Tencent and CEO of Tencent Cloud and Smart Industries Group, emphasized that the real-world value of artificial intelligence is...
Kickstarter Sponsors Wide Theatrical Release of Two Sleepy People, Championing Community-Backed Cinema AUSTIN, Texas, Jan. 21, 2026 /PRNewswire/ -- Kickstarter, the leading crowdfunding and launch platform for creative projects of every size, and Creator Camp, the creator-led film studio...
NEW YORK, Jan. 21, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of F5, Inc. (NASDAQ: FFIV) between October 28, 2024 and October 27, 2025, both dates inclusive (the "Class Period"), of the important February 17, 2026 lead...
SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the pricing of an upsized public offering of 22,500,000 shares of its common stock. The shares of common stock are being sold to the public at a price of $10.00 per share. All of the shares of common stock to be sold in the public offering are to be sold by Erasca. The gross proceeds to Erasca from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be $225.0 million. In addition, Erasca has granted the underwriters a 30-day option to purchase up to an additional 3,375,000 shares of common stock at the offering price, less underwriting discounts and commissions. The offering is expected to close on January 23, 2026, subject to the satisfaction of customary clos
SYDNEY, Jan. 21, 2026 /PRNewswire/ -- On November 18, 2025, GAC hosted its brand and new model launch ceremony in Sydney, officially unveiling its Australia Local Strategy—"GAC: Growing Australian Confidence"—the localized implementation of the company's global "One GAC 2.0" strategy. One...
NEW YORK--(BUSINESS WIRE)--Goldman Sachs BDC, Inc. (the “Company”) (NYSE: GSBD) announced today that it has priced an offering of $400 million aggregate principal amount of 5.100% notes due 2029 (the “Notes”). The Notes will mature on January 28, 2029 and may be redeemed in whole or in part at the Company’s option at any time at par plus a “make-whole” premium, if applicable. The Company intends to use the net proceeds of this offering to pay down debt under its revolving credit facility and fo
In the news release, PayJoy Delivers 40%+ Growth While Strengthening Income and Financial Stability for Underbanked and Gig Workers, issued 22-Dec-2025 by PayJoy over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with...
NEW YORK, Jan. 21, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. (NASDAQ: TNDM) resulting from allegations that Tandem Diabetes Care may have issued...
NEW YORK, Jan. 21, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of investors in cryptocurrency issued by Balancer (ticker: BAL), resulting from allegations that Balancer may have issued...
MIAMI, Jan. 21, 2026 /PRNewswire/ -- Aldabra 4 Liquidity Opportunity Vehicle, Inc. (the "Company"), a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one...
